News

A new analysis of data from the PIONEER AF-PCI clinical trial demonstrates that XARELTO® (rivaroxaban) is associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of...

Getinge announced Aetna, a leading health insurance benefits company in the United States, issued a Clinical Policy Bulletin (CPB) addressing peripheral vascular stents. Aetna issued a revised CPB stating that the iCast covered stent...

“IVUS is more accurate than angiography in measuring vessel dimensions. It facilitates achieving sufficient vessel lumen diameters and aids in evaluating the response of the target lesion to treatment,” said Young-Guk Ko, MD, the study’s lead...

"When compared to male patients, female patients often present with more advanced symptoms of heart valve disease, highlighting the importance of uncovering how we can best educate women on early warning signs and treatment options sooner,"...

Long-term durability data showed clinically meaningful, safe and sustained blood pressure (BP) reductions (-23.2 mmHg in office systolic BP and -14.0 mmHg reductions in 24-hour ambulatory BP) in patients with uncontrolled hypertension.

Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.

A late-breaking clinical trial confirms routine use of Impella CP in patients who have had a heart attack with STEMI cardiogenic shock reduces 180-day mortality by 12.7%, compared to the control arm (45.8% vs. 58.5%, p=0.04).

New data demonstrate the early addition of twice-yearly* Leqvio (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol...

The KARDIA-2 study achieved its primary endpoint demonstrating clinically and statistically significant additive, placebo-adjusted reductions of up to 12.1 mmHg in 24-hour mean systolic blood pressure (SBP) measured by ambulatory blood...

Withdrawing aspirin one month after percutaneous coronary intervention (PCI) in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared to patients...